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Highlights 
 The study of benign neoplasms may reveal relevant aspects of malignant 
progression 
 Oncogenic mutations considered drivers of cancers are reported in 
benign lesions 
 The role of oncogenic mutations seems to be context dependent 
 Pathogenic mutations affecting the same pathway are seen in different 
tumours 
 Molecular studies can guide  therapeutic approaches towards 
odontogenic lesions 
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Abstract 
The first step towards the prevention of cancer is to develop an in-depth 
understanding of tumourigenesis and the molecular basis of malignant 
transformation. What drives tumour initiation? Why do most benign tumours fail 
to metastasize? Oncogenic mutations, previously considered to be the hallmark 
drivers of cancers, are reported in benign cysts and tumours, including those 
that have an odontogenic origin. Despite the presence of such alterations, the 
vast majority of odontogenic lesions are benign and never progress to the stage 
of malignant transformation. As these lesions are likely to develop due to 
developmental defects, it is possible that they harbour quiet genomes. Now the 
question arises – do they result from DNA replication errors? Specific candidate 
genes have been sequenced in odontogenic lesions, revealing recurrent BRAF 
mutation in the case of ameloblastoma, KRAS mutation in adenomatoid 
odontogenic tumours, PTCH1 mutation in odontogenic keratocysts, and 
CTNNB1 (Beta-catenin) mutation in calcifying odontogenic cysts. Studies on 
these benign and rare entities might reveal important information about the 
tumorigenic process and the mechanisms that hinder/halt neoplastic 
progression. This is because the role of relatively common oncogenic mutations 
seems to be context dependent. In this review, each mutation signature of the 
odontogenic lesion and the affected signalling pathways are discussed in the 
context of tooth development and tumorigenesis. Furthermore, behavioural 
differences between different types of odontogenic lesions are explored and 
discussed based on the molecular alteration described. This review also 
includes the employment of molecular results for guiding therapeutic 
approaches towards odontogenic lesions. 
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Introduction 
The compilation of a Precancer Atlas has been proposed to integrate 
large-scale research and thus improve the understanding of the events that 
drive oncogenesis [1]. The study of benign tumours is considered as important 
as the study of malignant ones, as they may reveal relevant aspects of 
neoplastic progression [2]. The genomic stability inherent in benign tumours 
contributes to the identification of remarkably clear genetic fingerprints, pointing 
to specific molecular alterations that are likely to be responsible for 
tumorigenesis. 
In a similar fashion to malignant neoplasms, benign tumours harbour one 
or several oncogenic mutations that lead to clonal cell proliferations. Notably, 
benign tumours share five of the six putative “hallmarks of cancer”, with 
metastasis being the exception [3,4]. It is intriguing that some benign tumours 
lack fibrous capsules and can show markedly aggressive behaviour, while 
others grow no more than a few cubic centimetres inside a thick fibrous 
capsule. Odontogenic lesions mainly comprise benign cysts and neoplasms of 
the tooth apparatus, including lesions that can perforate the cortical plate and 
infiltrate the soft tissues, such as ameloblastomas, and encapsulated lesions 
with indolent behaviour, such as adenomatoid odontogenic tumour (AOT). 
These benign tumours can harbour oncogenic genetic alterations that were 
previously considered as the drivers of specific, invasive cancers originated in 
other organs, such as melanomas, lung and colorectal adenocarcinomas [5]. It 
is not clear why the majority of the benign conditions never progress to cancer, 
even in the presence of pathogenic mutations. In this review, we used the 
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odontogenic cysts and tumours as the models to discuss the context-specific 
role of oncogenic signalling pathways, which are important for understanding 
tumour biology in a broader perspective. 
The morphology of odontogenic lesions resembles the stages of tooth 
embryonic development (i.e. odontogenesis) (Figure 1), while the molecular 
mechanisms associated with odontogenesis have been associated with the 
pathobiology of such entities. While in ameloblastomas, the gene expression 
profile reflects differentiation from the dental lamina towards the cap/bell stage 
of tooth development, odontogenic keratocysts (OKCs) show differentiation 
toward keratinocytes [6]. Every step of normal odontogenesis is regulated by 
BMP, FGF, Shh and Wnt cell signalling pathways [7]. During the past years, 
pathogenic gene mutations affecting downstream signalling cascades of these 
signalling pathways were described in odontogenic lesions, including BRAF 
mutation in ameloblastoma, KRAS mutation in AOT, PTCH1 mutation in OKC, 
and CTNNB1 (Beta-catenin) mutation in calcifying odontogenic cyst (COC). 
In this review, we discuss the mutation signatures of some odontogenic 
cysts and tumours, together with their significance in cell signalling pathways in 
the context of odontogenesis and tumorigenesis. Furthermore, insights into the 
histopathogenesis and behavioural differences between the lesions are brought 
into light on the basis of the described molecular alterations.  
The MAPK pathway, ameloblastoma and adenomatoid odontogenic 
tumour  
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The prototypical MAPK cascade, the Ras-Raf-MEK-ERK, is commonly 
dysregulated in several human cancers. In this pathway, the activation of a 
family of cell-surface tyrosine kinase receptors triggers the proteins of the Ras 
superfamily of small GTPases, which includes molecules encoded by KRAS, 
HRAS, and NRAS [8]. Activated Ras binds and activates Raf kinases, encoded 
by BRAF, RAF1, and ARAF. Raf phosphorylates and activates MEK1/2, which 
in turn phosphorylates and activates ERK-1/2. ERKs phosphorylate a vast array 
of substrates both in the cytosol and in the nucleus [9] (Figure 2), including 
receptors, protein kinases, signalling effectors, and transcription factors. 
Recently, alterations of prototypical MAPK cascade components were reported 
in a high proportion of benign odontogenic lesions, mainly in ameloblastoma 
and AOT [10,11]. 
The activating mutation BRAFV600E occurs in 60–80% of 
ameloblastoma cases, regardless of clinical and histopathological variants, 
including its malignant counterpart, ameloblastic carcinoma (AC) [10,12–15]. 
Interestingly, MAPK activation had previously been detected by 
immunohistochemistry in ameloblast-like cells neighbouring the basement 
membrane of ameloblastomas, as well as in tooth germs [16]. Other 
odontogenic lesions were also shown to be BRAFV600E positive, including 
clear cell odontogenic carcinoma, ameloblastic fibroma, ameloblastic 
fibrodentinoma, and ameloblastic fibro-odontoma [12,13,17]. 
Genetic mutations mutually exclusive of BRAFV600E, such as those in 
KRAS, NRAS, HRAS, and FGFR2, were described in BRAF wild-type 
ameloblastomas [12,14]. Additionally, a high-density whole-genome microarray 
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analysis showed only a few rare DNA copy-number alterations, mostly affecting 
genes associated with MAPK activation [18]. These results support the crucial 
role of the MAPK pathway activation in the pathogenesis of ameloblastomas. 
Secondary events, such as changes in tumour suppressor genes, may also play 
a role in cytodifferentiation and tissue structuring of these neoplasms [19,20]. 
The MAPK pathway is also altered in AOT, which is similar to 
ameloblastoma – an epithelial odontogenic neoplasm (Figure 2). In 2016, we 
reported the activating pathogenic mutation KRASG12V in 7/9 AOT samples by 
carrying out a targeted next-generation sequencing approach in a panel 
containing ~2,800 COSMIC mutations in 50 genes [11]. Even though 
ameloblastoma and AOT neoplasms harbour gene mutations affecting MAPK 
cascade, their clinical behaviours are markedly distinct. While ameloblastoma is 
locally aggressive and can perforate the cortical bone plate and infiltrate soft 
tissues, AOT is encapsulated with limited growth potential and very low 
tendency of recurrence. Notably, both the odontogenic tumours show 
expression of the MAPK transcriptional targets, cyclin-D1 and c-Myc, which 
regulate cell proliferation [21–25]. In colorectal cancer, it has been shown that 
BRAFV600E and KRASG12V oncogenes have a different impact on 
morphology and invasive phenotype [26]. Furthermore, in contrast to 
KRASG12V, BRAFV600E caused an increased expression of unique target 
genes, such as SOX2 [27]. In lungs, different tumorigenic capacity of oncogenic 
BRAF and KRAS were reported [28,29]. On this basis, although MAPK pathway 
is activated in ameloblastoma and AOT, distinct roles of BRAF and KRAS 
oncogenes within each tumour context, including the cell-of-origin and the 
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prevalent location at the jaws, may account for the distinct biological behaviour 
of these neoplasms.   
The high prevalence of mutations affecting MAPK signalling pathway in 
ameloblastoma and AOT indicates that this is likely an early pathogenic event. 
The evidence that MAPK cascade plays a central role in odontogenesis, 
including ameloblast development, has shed light on the intimate connection 
between oncogenic MAPK signalling, ameloblastoma, and AOT tumorigenesis, 
as we discuss below. 
Growth factors, such as FGF and EGF, are the major regulators of the 
MAPK cascade in many physiological and cellular contexts, including 
odontogenesis. At the bell stage of tooth development, the downregulation of 
FGFR-2, a FGF receptor, was reported in the pre-ameloblast cells [30] in 
association with the cessation of cell proliferation [31]. Curiously, FGFR-2 was 
found to be over activated by mutation in some ameloblastoma samples [14], 
suggesting that a sustained hyper-proliferation is mediated by oncogenic FGF 
signalling. Corroborating these findings, treatment with FGF ligands lead to 
ameloblastoma cultured cells’ increased proliferation through ERK-1/2 
signalling, an effect blocked by MEK inhibition [32]. 
The EGF receptor, erbB-1, is encoded by EGFR, and its abnormal 
function is implicated in tumorigenesis [33,34]. The expression of EGFR in 
ameloblasts varies throughout the developmental stages. It is expressed in the 
inner enamel epithelium (IEE), which contains proliferative and differentiating 
cells, while it is expressed in low levels in polarizing ameloblasts, and its 
expression remains low during the enamel secretion stage [35]. Interestingly, 
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EGFR is overexpressed in ameloblastomas [10,36], in a similar fashion to other 
epithelial neoplasms such as head and neck, cervical, and oesophageal cancer 
[37]. In ameloblastoma cultured cells, EGFR knockdown blocked the activity of 
matrix metalloproteinases (MMPs), and abolished EGF-stimulated cell migration 
and invasion [38]. 
In addition to studies with human tumours and in vitro experimentation, in 
vivo experiments support that MAPK pathway dysregulation impacts the 
ameloblasts’ function. Activation of MAPK cascade caused by HrasG12V 
mutation led to compromised proliferation and differentiation of enamel-
producing ameloblasts and their precursors in mice incisors [39]. Notably, 
HrasG12V ameloblasts were shown to be disorganised and with abnormal cell 
polarity [39], a characteristic shared with ameloblast-like cells in ameloblastoma 
and AOT. Further analyses supported the conclusion that low levels of 
phosphorylated ERK-1/2 (i.e. the MAPK downstream effector) might be 
necessary for the normal ameloblast progenitors to exit the cell cycle and to 
differentiate [39]. Studies with Hras transgenic mice reported the development 
of jaw tumours compatible with the diagnosis of odontogenic tumours [40–42].  
MAPK-targeted therapy has been tested in ameloblastoma cells in vitro. 
Treatment with erbB-1 monoclonal antibodies (cetuximab and panitumumab) 
and erbB-1 tyrosine kinase inhibitors (erlotinib, gefitinib, and AG1478) resulted 
in ameloblastoma cell growth suppression [10]. Conversely, resistance to erbB-
1 inhibition was observed in BRAFV600E ameloblastoma cells [10]. Such 
resistance to ErB-1 inhibition was attributed to nuclear translocation of erbB-1 in 
certain cancer types [43]. This erbB-1 nuclear localization was observed in 
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ameloblastomas by Pereira and colleagues [21], raising a concern about an 
additional resistance mechanism of anti-erbB-1 therapy in ameloblastomas [21]. 
In addition to in vitro testing, BRAF-mutant targeted therapy has already been 
clinically tested in human ameloblastomas [44,45]. In one case, a patient with 
metastatic ameloblastoma was treated with a dual therapy with BRAF/MEK 
inhibition (dabrafenib and trametinib) [44], whereas in the other case, a patient 
with recurrent ameloblastoma received only dabrafenib [45]. Both the case 
reports described a reduction in the tumour mass and suggested the possibility 
of using neoadjuvant and/or adjuvant targeted therapy in a subset of aggressive 
ameloblastoma undergoing surgery [44,45]. However, there are important 
adverse effects of this treatment, and its long-term complications include an 
increase in the chances of developing squamous cell carcinomas. 
Shh pathway and odontogenic keratocyst 
In mammals, there are three Hedgehog-family members, SHH, IHH and 
DHH. SHH triggers short and long-range signalling activities [46,47]. The Shh 
signalling activity takes place after the secreted ligand undergoes a series of 
post-translational modifications, including a covalent modification by a 
cholesterol moiety added to its carboxyl-terminal domain and attachment of a 
palmitic acid group to its amino-terminal end [48]. Cooperation between two 
transmembrane proteins, Dispatched and SCUBE2, culminates with the SHH 
release from the surface of the signalling cells [49,50]. The secreted SHH ligand 
binds to its receptor PTC1, a twelve-pass transmembrane protein, encoded by 
PTCH1 [51]. In the absence of its ligand, PTC1 works as a ligand-independent 
inhibitor of the downstream SMO, a seven-pass transmembrane protein 
14 
 
member of the G-protein coupled receptor superfamily [50,52]. The current 
concept is that this is not a direct inhibition, as biochemistry assays 
demonstrated that PTC1 and SMO do not physically interact [53].  
The fine-tuning of SHH activity has recently been shown to take place in 
the primary cilium, a nonmotile microtubule-based organelle present in most 
mammalian cells, by an as-yet-undefined mechanism [54,55]. Once the 
repression exerted by PTC1 is released, the resulted increase in ciliary levels of 
SMO leads to processing of GLI1-3 transcription factors [56–58] (Figure 2). 
While GLI3 can be proteolytically processed and work both as a repressor or an 
activator of the pathway, GLI1 and GLI2 act as activators. Overall, the different 
concentration thresholds of GLI is sufficient to mediate graded Shh signalling 
[59]. 
PTCH1 mutation leads to constitutive activation of the Shh pathway, and 
it is considered as the major mechanism underlining OKC tumorigenesis [60]. 
OKC occurs in isolation or as part of the nevoid basal cell carcinoma syndrome 
(NBCCS) (OMIM #109400) [61]. In 1996, PTCH1 genetic mutation was reported 
as the underlying cause for NBCCS [62,63]. Subsequently, loss of 
heterozygosity (LOH) and mutations at PTCH1 were reported in syndromic and 
sporadic OKCs [64–66]. Recently, the DNA analysis of the microdissected OKC 
epithelium revealed that a PTCH1 genetic alteration is present in ~80% of the 
sporadic OKC [67]. Activating SMO mutations [68],as well as transcriptional and 
immunohistochemical studies reinforce Shh pathway over activation in human 
OKC [60,69,70]. In vivo, Ptch1 knockout and constitutive activation of Gli2 were 
reported to drive mandibular OKC-like lesions in mice [71,72]. This evidence 
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strengthens the link between Shh signalling pathway misregulation and OKC 
tumorigenesis. 
Despite the exciting possibility of PTCH1 mutations being an OKC 
signature, LOH at the PTCH1 loci occurs in other odontogenic lesions such as 
the orthokeratinized odontogenic cyst and ameloblastomas [73–76]. Also, 
PTCH1 mutation was previously described in the calcifying epithelial 
odontogenic tumour (CEOT) [77]. However, the effects of these genetic 
alterations in PTC1 function were not determined. 
Although OKC was recently reclassified by World Health Organization 
(WHO) as an odontogenic cystic lesion [78], numerous studies have considered 
it as a true cystic neoplasm. OKC epithelium has an intrinsic growth potential 
that is not seen in other cysts, and this lesion presents an elevated recurrence 
rate of 30% [79]. Moreover, OKC can attain a large size resulting in massive 
bone destruction [79].  
In the past, the concept of “primordial cyst” was used to refer to OKC. 
The cyst was believed to have a primordial origin, arising from the dental lamina 
(tooth bud) before enamel formation had taken place, and even by substituting 
a tooth [80]. A recent study showed that OKC cells harbour expression profiles 
similar to keratin-producing cells (i.e. keratinocytes) [6]. In this study, Affymetrix 
whole-genome arrays were used to hybridise total RNA from 12 sporadic OKC. 
In addition to Shh pathway genes, squamous and terminal epithelial 
differentiation markers were found to be overexpressed [6]. This study provided 
molecular evidence to support the concept that OKC originates from fetal oral 
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epithelium or dental lamina at early stages of odontogenesis rather than the 
enamel organ (Figure 1).  
It is well known that Shh signaling has pivotal roles in early 
odontogenesis, stimulating epithelial cell proliferation to drive the formation and 
growth of the tooth bud and increasing epithelial cell survival during the 
development of the cap-staged tooth germs [81]. One of the most important 
targets of Shh signalling is BCL2, which encodes a pro-survival protein. In 
human tooth germs, a strong immunoexpression of Bcl-2 occurs in the dental 
lamina and tooth bud, the most primitive form of odontogenic epithelium [82]. 
Moreover, Bcl-2 protein was also observed in dental lamina cells even when it is 
fragmented into cell nests, but it disappears after squamous maturation [82]. 
Interestingly, Bcl-2 overexpression is a hallmark of OKC epithelium [83] and 
basal cell carcinoma (BCC) [84]. We propose the hypothesis that during OKC 
tumorigenesis, Shh misregulation might lead to persistent Bcl-2 production in 
the primitive odontogenic epithelium, reactivating its proliferative and survival 
potential. Supporting this hypothesis, mice overexpressing the Shh pathway 
effector GLI2, under the control of keratin 5 promoter, were shown to develop 
OKC-like and Bcl-2-expressing BCC-like lesions [72,85]. Although a direct link 
between Bcl-2 overexpression and Shh pathway misregulation were only 
analysed in the BCC [85], it is very likely that Bcl-2 overexpression at OKC 
epithelium line is driven by Shh signalling activation.  
Another important gene regulated by Shh signalling in several contexts is 
the transcription factor SOX-2 [86], which is a marker of stem cells and 
progenitor cells in epithelial tissues [87]. During tooth development in mammals, 
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SOX-2 is associated with the epithelial competence of dental lamina, both for 
the successional tooth formation and the serial addition of molars [88]. SOX-2 
expression was also described in dental lamina and in its fragments associated 
with the developing third and fourth molars [88,89]. Interestingly, this 
transcription factor is implicated in cell proliferation and self-renewal in the Shh-
associated tumours [86,90] and was also reported to be highly expressed in 
basal and suprabasal epithelial cell layer of OKC [6,91]. These findings support 
the idea that Shh-associated OKC arises from SOX-2-positive dental cells [6], 
especially those cells located at the posterior extension of the dental lamina in 
the mandible, the site most frequently affected by some odontogenic lesions 
(Figure 3). Likewise, SOX-2-positive cells are linked with odontoma, 
ameloblastoma, and AC tumorigenesis (Figure 3) [92–94]. 
As the alteration in Shh signalling is the main feature in OKC, the 
pathway inhibitors have been tested therapeutically. In OKC primary cultured 
cells, the use of the SMO antagonist cyclopamine showed a dose-dependent 
growth arrest of the cells, together with Shh pathway downregulation [95]. A 
nearly complete resolution of three NBCCS-associated OKC was reported in 
one case of a 55-year-old man after administration of Shh signalling antagonist 
GDC-0449 (Vismodegib) [96]. The effects of Vismodegib were later tested in a 
clinical trial study and an overall OKC size reduction in four out of six NBCCS 
patients was reported [97].  
The Wnt pathway and calcifying odontogenic cyst 
The canonical Wnt pathway activation involves binding of Wnt ligands to 
the frizzled receptors and the co-receptor LRP-5/6. Once Wnt binds to the 
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receptor complex, a signal is transduced to the cytoplasmic phosphoprotein 
DVL-1 and it induces events that disrupt the multiprotein “destruction complex” 
of Beta-catenin (encoded by CTNNB1), formed by Axin-1, APC, GSK3B, and 
CKI-alpha. Once stabilised and accumulated in the cytoplasm, Beta-catenin is 
translocated into the nucleus and exerts its effect by binding with the 
transcription-factors TCF/LEF-1, promoting downstream gene expression [98] 
(Figure 2). Beta-catenin accumulation in the cytoplasm and nucleus is a 
hallmark of canonical Wnt pathway activation. Abnormal activation of the Wnt 
pathway is associated with the pathogenesis of several types of cancer [99] and 
odontogenic lesions, especially COC. 
In a study in 2003, an abnormally-strong nuclear and cytoplasmic Beta-
catenin immunostaining was reported in 6/6 cases of COC [100]. Subsequently, 
CTNNB1 DNA sequencing with primers spanning the phosphorylation site for 
GSK3B revealed genetic mutations in 10 COC samples [101]. Nuclear co-
expression of LEF-1 and Beta-catenin were also reported in COC [102]. In 
2016, de Sousa and her colleagues simultaneously interrogated ~2800 somatic 
mutations in 50 oncogenes and tumour suppressor genes in three COC cases 
[103]. The only pathogenic genetic alteration found was in CTNNB1, supporting 
the concept that constitutive activation of the Wnt signalling pathway through 
Beta-catenin mutation is the pivotal event underlining the COC tumorigenesis.  
Besides COC, the dentinogenic ghost cell tumour (DGCT) and the ghost 
cell odontogenic carcinoma (GCOC) were found to harbour CTNNB1 genetic 
alterations at different codons [104,105]. Furthermore, the nuclear and 
cytoplasmic Beta-catenin accumulation were observed in all these lesions by 
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immunohistochemistry [105], indicating that aberrant signalling in odontogenic 
epithelium coordinated by Beta-catenin plays a role in their pathogenesis. 
Notably, COC, DGCT and GCOC can form dentinoid material or odontoma-like 
structures (Figure 1). The formation of dental hard tissues is intimately 
associated with the crucial role of Wnt signalling pathway in inducing tooth 
formation. For example, the Wnt activation by Ctnnb1 mutation or Apc deletion 
in mouse’s oral epithelium generated ectopic teeth formation [106–108]. 
Furthermore, the constitutive activation of Beta-catenin in dental epithelium was 
shown to lead to the formation of odontoma-like lesions with osteodentine and 
dysplastic dentine in mice jaw, as we detail later [93]. 
Wnt/Beta-catenin signalling is considered a potent regulator of calcified 
tissue development and homeostasis in many contexts, such as bones and 
teeth. Over-activity of Wnt signalling caused by persistent Beta-catenin 
stabilisation in the dental mesenchyme induced excessive dentin and 
cementum formation [109]. Conversely, Wnt pathway inhibition by 
overexpression of Dkk-1 in mice odontoblasts impaired dentin formation in 
mandibular molars [110]. An attractive hypothesis is that the over-activity of 
mutated Beta-catenin in epithelial cells of COC might cause aberrant signalling 
networks of communication with stromal cell compartments, resulting in the 
production of abnormally calcified dentin-like material, which explains odontoma 
formation in this lesion. In fact, the paracrine induction of surrounding tissues 
induced odontoma-like lesions in mice conditionally mutated for Beta-catenin 
[93]. In this enlightening study, a non-degradable form of Beta-catenin was 
conditionally expressed in mice in a Sox2-expressing subset of dental epithelial 
stem cells after the cessation of normal tooth induction. Remarkably, these mice 
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showed calcified structures that histologically resembled the odontomas. The 
odontoma-like structures had only a partial contribution of cells derived from the 
epithelium sustaining a Beta-catenin mutation, suggesting that the tumour is 
also derived from adjacent wild-type mesenchymal tissue [93]. 
The Wnt ligand WNT5A is also related to the development of dental hard 
tissue and odontogenic lesions. Wnt5a-deficient mice exhibited reduced levels 
of cell proliferation in the dental epithelium and delayed odontoblast 
differentiation [111]. In human dental papilla cells, WNT5A overexpression 
increased the formation of calcified nodules [112]. Interestingly, WNT5A 
overexpression was reported in COC [113] and ameloblastomas [114]. In 
enamel epithelium cultured cells, WNT5A overexpression resulted in 
tumorigenic properties, such as growth factor independence [114], suggesting a 
role of WNT5A in the biology of ameloblast-like cells in odontogenic tumours. 
Ghost cells are a common histological finding in COC. These cells may 
accumulate enamel-related proteins and undergo calcification [115]. 
Interestingly, COC ghost cells express WNT1 and WNT5A ligands, as well as 
Beta-catenin [116,117]. In immature odontomas, ghost cells showed weak 
Beta-catenin immunostaining, while adjacent epithelial cells exhibited a strong 
pattern in the nucleus and cytoplasm. Moreover, a positive staining for LEF-1 
was found in the cytoplasm of the ghost cells and in the nucleus of adjacent 
odontogenic epithelial cells [118]. These results provide further support to the 
idea that the Wnt signalling is involved in the formation of the ghost cells.  
Odontogenic lesions, mainly COC, are of particular interest, as they are 
well known to have striking histological similarities with the brain tumour 
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craniopharyngioma. This can be attributed to their common embryologic origin 
from oral ectoderm [119]. The calcified material, ghost cells, and the CTNNB1 
mutation are common findings in the adamantinomatous tumour subtype, which 
frequently mimics COC histology [119,120]. Conversely, the papillary 
craniopharyngioma subtype is highly correlated with recurrent BRAFV600E 
mutations and lacks ghost cells and calcifications [120]. These observations 
further strengthen the link between Wnt/Beta-catenin pathway activation and 
formation of ghost cells and calcified structures.  
Taken together, Beta-catenin plays a role in the tumorigenesis of COC. 
Also, the association of abnormal Wnt signalling with ghost cells and dental 
hard-tissue pathobiology, including odontoma formation, have provided a clue 
to the mechanism underlining the histopathogenesis of COC and tumours 
containing ghost cells. 
Concluding remarks 
Benign lesions can share driver oncogenic mutations that were 
previously thought to be exclusive to malignant neoplasms. The fact that these 
benign conditions virtually never convert to a malignant disease, even in the 
presence of such pathogenic mutations, is intriguing. The understanding of the 
tumorigenic process and mechanisms that confine cysts and tumours to a 
benign state should be explored in each organ’s context for cancer prevention 
and therapy.  
Tumours should, therefore, be considered as an abnormal organ. 
Odontogenic cysts and tumours are abnormal tooth organs, and here we have 
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reviewed their main genetic alterations (for those lesions already studied) in the 
context of odontogenesis. Odontogenesis is governed by sequential and 
reciprocal epithelial-mesenchymal interactions, and as a reflection of that, the 
induction of a stromal component by mutated dental epithelium plays a role in 
the formation of odontogenic lesions. The use of cell culture models that mimic 
all the lesion compartments is urged for the unbiased study of these entities. 
In addition, we must consider the developmental setting and the genomic 
landscape to better understand the tumorigenic role of central signalling, such 
as MAPK, Shh and Wnt pathways. As odontogenic cysts and tumours probably 
arise due to developmental defects, and no environmental mutation sources 
have been identified as a causative for them, they probably harbour quiet 
genomes similar to some paediatric tumours.  
Different odontogenic cysts and tumours arise from different stages of 
dental lamina cells, as evidenced by their histopathologic features that 
resemble the embryologic patterns seen in the developing tooth. Pathogenic 
mutations affecting the same pathway are seen in different tumours, reinforcing 
the idea that the cell of origin, including its location in the jaws, is dominant to 
oncogenic signalling in these kinds of tumours. 
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Figure 1. Schematic illustration of odontogenic cysts and tumours 
histopathologic features that resemble, in part, embryologic patterns seen 
in the developing tooth. (A) Tooth development is divided into initiation, bud, 
cap, and bell stages, followed by root formation and eruption. At initiation, 
epithelial thickening invaginates into the underlying mesenchyme to form a bud 
shape. In the cap stage, the enamel knot (+), and the enamel organ are formed. 
The stellate reticulum consists of star-shaped epithelial cells and is formed in 
the middle of the enamel organ, between inner and outer enamel epithelium 
(IEE and OEE, respectively). During the bell stage, ameloblasts differentiate 
from the IEE and odontoblasts from the dental mesenchyme (dental papilla). 
Later, deposition of the extracellular matrices of dentin and enamel begins. (B) 
Odontogenic keratocyst (OKC) epithelium is characterized by a parakeratinized-
stratified squamous epithelium with columnar epithelial cells at basal layer. OKC 
arises from cells of the early stage of odontogenesis before enamel organ 
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formation has taken place, and sometimes it might form from tooth bud instead 
of a tooth. Ameloblastoma and calcifying odontogenic cyst (COC) are lesions of 
the enamel organ and present ameloblast-like cells with reversely polarised 
nuclei and stellate reticulum-like cells. While in ameloblastomas there is no 
induction of hard-tissue formation, COC can present calcification (dentinoid-like 
material, adjacent to epithelial component and dystrophic mineralisation of 
ghost cells). 
 
Figure 2. Cell signalling alterations in odontogenic cysts and tumours. 
MAPK, Shh and Wnt signalling pathways play a role in every step of normal 
tooth development, and genetic alterations affecting these pathways (grey 
boxes) occur in a set of odontogenic cysts and tumours. Activating mutation in 
the Ras GTP-binding protein (KRAS) and Raf kinase (BRAF) in adenomatoid 
odontogenic tumour and ameloblastoma, respectively, results in over activity of 
ERK-1/2 kinase in cytoplasm and nucleus. Inactivation of the transmembrane 
receptor PTC1 in odontogenic keratocyst results in the constitutive production of 
the active form of transcription factor GLI (GLI-A), increasing the expression of 
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target genes. Gain-of-function mutations in Beta catenin (CTNNB1) in COC 
result in stabilisation, translocation to the nucleus, and activation of 
transcription. Ultimately, alterations of these pathways in odontogenic cysts 
result in increased cell proliferation. PM, plasmatic membrane; e, expression. 
 
Figure 3. Schematic illustration of cells’ source for tooth development and 
odontogenic cysts and tumours. Odontogenic cysts and tumours arise from 
cells that participate in tooth formation and replacement. (A) At the cap stage of 
the deciduous tooth (1st), the dental lamina on the lingual side (successional 
dental lamina) grows into the underlying mesenchyme towards the apex of the 
deciduous tooth (2nd). Later, the dental lamina connecting the primary teeth to 
the oral epithelium and the successional lamina connecting the deciduous and 
the permanent teeth are degraded, forming dental lamina remnants. Root 
development is guided by Hertwig’s epithelial root sheath (HERS) that fragment 
when the tooth erupts, forming the epithelial cell rests of Malassez (ERM) on 
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the root surface. (B) The permanent molars form posteriorly to the deciduous 
teeth and are not replaced. The primary molars erupt in a specific sequence 
(M1, molar 1; M2, molar 2; M3, molar 3) from the posterior extension of the 
dental epithelium. Dental lamina and its fragment cells expressing SOX-2 are 
associated with the development of third and fourth molars and with 
odontogenic cysts and tumours formation (arrowheads). 
 
 
 
